[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100603460":3},{"organization":4,"outcomesModule":7,"designInfo":16,"detailedDescription":11,"studyPopulation":11,"armGroups":26,"interventions":39,"overallOfficials":11,"centralContacts":47,"locations":11,"responsibleParty":53,"collaborators":11,"id":55,"slug":11,"hasResults":56,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":11,"eligibilityCriteria":60,"healthyVolunteers":56,"sex":61,"minAge":62,"maxAge":63,"enrollmentInfo":64,"targetDuration":11,"studyType":67,"phases":68,"briefSummary":70,"conditions":71,"keywords":11,"overallStatus":73,"whyStopped":11,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":11},{"fullName":5,"class":6},"VivaVision Biotech, Inc","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in anterior chamber cell (ACC) grade in the study eye at Day 14",null,"Day 14",[14],{"measure":15,"description":11,"timeFrame":12},"The proportion of subjects with ACC grade of 0 in the study eye at Day 14",{"allocation":17,"interventionModel":18,"interventionModelDescription":11,"primaryPurpose":19,"observationalModel":11,"timePerspective":11,"maskingInfo":20},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":21,"maskingDescription":11,"whoMasked":22},"TRIPLE",[23,24,25],"CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR",[27,33],{"label":28,"type":29,"description":30,"interventionNames":31},"VVN461, 1.0%","EXPERIMENTAL","VVN461 Ophthalmic Solution, 1.0%",[32],"Drug: VVN461 Ophthalmic Solution 1.0%",{"label":34,"type":35,"description":36,"interventionNames":37},"1.0% prednisolone acetate","ACTIVE_COMPARATOR","1.0% prednisolone acetate, Pred Forte",[38],"Drug: 1.0% prednisolone acetate",[40,45],{"type":41,"name":42,"description":43,"armGroupLabels":44,"otherNames":11},"DRUG","VVN461 Ophthalmic Solution 1.0%","1 drop for study eye each time, 6 times daily (Q2h) for 7 days; 4 times daily (QID) for 7 days; 2 times daily (BID) for 7 days; 1 time daily for 7 days",[28],{"type":41,"name":34,"description":43,"armGroupLabels":46,"otherNames":11},[34],[48],{"name":49,"role":50,"phone":51,"phoneExt":11,"email":52},"Caroline Lu","CONTACT","+8618816562189","caroline.lu@vivavisionbio.com",{"type":54,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100603460",false,"NCT07136805","A Phase 3 Study of VVN461 Ophthalmic Solution for Noninfectious Anterior Uveitis","A Multi-center, Randomized, Single-masked, Active-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of 1.0% VVN461 Ophthalmic Solution in Patients With Non-infectious Anterior Uveitis","Inclusion Criteria:\n\n* At the time of signing the informed consent form (ICF), the subject must be aged 18 to 70 years (inclusive);\n* At screening, the affected eye is diagnosed with non-infectious anterior uveitis (acute or recurrent acute, only unilateral eye affected patients are included);\n* At screening, the ACC grade of the affected eye is 2+ or 3+ \\[SUN criteria\\];\n* At screening, the ACF grade of the affected eye is ≥1 \\[SUN criteria\\];\n\nExclusion Criteria:\n\n* At screening, the affected eye has an ACC grade of 4+ or hypopyon\n* Diagnosis of intermediate uveitis, posterior uveitis, or panuveitis in either eye at the time of screening","ALL","18 Years","70 Years",{"count":65,"type":66},152,"ESTIMATED","INTERVENTIONAL",[69],"PHASE3","This is a multicenter, randomized, single-masked, active-controlled, parallel, Phase III pivotal study in China",[72],"Non-infectious Anterior Uveitis","NOT_YET_RECRUITING","2025-08-15",{"date":76,"type":77},"2025-08-22","ACTUAL",{"date":79,"type":66},"2025-10-01",{"date":81,"type":66},"2027-04-30",{"name":5,"class":6}]